Oncocyte amends CEO employment agreement; removes 800,000-share performance option grant

Insight Molecular Diagnostics Inc.

CEO Joshua Riggs' 800,000-share performance option grant eliminated under amendment dated July 13, 2023.
Company may grant new performance-based options if shareholders approve plan amendment to remove annual individual limit.
Amendment also modifies equity vesting acceleration provisions for time-based awards in certain termination scenarios.
Base salary remains $360,000; target bonus unchanged at 50% of base salary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.